Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Surgery
Published in: BMC Surgery 1/2022

Open Access 01-12-2022 | Metastasis | Research

Indications for resection of recurrent lesions in patients with distal cholangiocarcinoma based on prognostic factors: a single-institute retrospective study and brief literature review

Authors: Taro Mashiko, Toshihito Ogasawara, Yoshihito Masuoka, Shigenori Ei, Shinichiro Takahashi, Masaki Mori, Kazuo Koyanagi, Seiichiro Yamamoto, Toshio Nakagohri

Published in: BMC Surgery | Issue 1/2022

Login to get access

Abstract

Background

To evaluate the effectiveness of surgery for recurrent distal cholangiocarcinoma and determine surgical indications based on prognostic factors for the recurrence of distal cholangiocarcinoma.

Methods

We analysed the outcomes of 101 patients who underwent surgical resection for distal cholangiocarcinoma between 2000 and 2018. The clinicopathological factors and prognosis of primary and recurrent distal cholangiocarcinoma were investigated.

Results

Of the 101 patients with resected distal cholangiocarcinoma, 52 (51.5%) had relapsed. Seven (13.5%) and 45 patients (86.5%) underwent resection of recurrent lesions and palliative therapy, respectively. There were no major complications requiring therapeutic intervention after metastasectomy. The median overall survival in patients with and without surgery for recurrent lesions was 83.0 (0.0–185.6) and 34 months (19.0–49.0), respectively. Therefore, patients who had undergone surgery for recurrent lesions had a significantly better prognosis (p = 0.022). Multivariate analyses of recurrent distal cholangiocarcinoma revealed that recurrence within one year was an independent predictor of poor survival. Resection of recurrent lesions improved prognosis.

Conclusions

Radical resection in recurrent distal cholangiocarcinoma may improve the prognosis in selected patients. Although time to recurrence is considered an important factor, the small number of cases of recurrence and resection of recurrent lesions in this study makes it difficult to conclude which patients are best suited for resection of recurrent lesions. This issue requires clarification in a multicentre prospective study, considering patients’ background, such as the recurrence site and number of metastases.
Literature
1.
Khan AS, Dageforde LA. Cholangiocarcinoma. Surg Clin North Am. 2019;99:315–35.CrossRef
2.
Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996;224:463–73.CrossRef
3.
Choi SB, Han HJ, Park PJ, Kim WB, Song TJ, Kim JS, et al. Disease recurrence patterns and analysis of clinicopathological prognostic factors for recurrence after resection for distal bile duct cancer. Am Surg. 2015;81:289–96.CrossRef
4.
Koyama K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A, et al. Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg. 2017;104:426–33.CrossRef
5.
Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, et al. Recurrence and prognostic factors of ampullary carcinoma after radical resection: comparison with distal extrahepatic cholangiocarcinoma. Ann Surg Oncol. 2007;14:3195–201.CrossRef
6.
Ishihara S, Horiguchi A, Miyakawa S, Endo I, Miyazaki M, Takada T. Biliary tract cancer registry in JAPAN from 2008 to 2013. J Hepatobiliary Pancreat Sci. 2016;23:149–57.CrossRef
7.
Hong SM, Pawlik TM, Cho H, Aggarwal B, Goggins M, Hruban RH, et al. Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. Surgery. 2009;146:250–7.CrossRef
8.
Miyazaki M, Shimizu H, Yoshitomi H, Kato A, Furukawa K, Takayashiki T, et al. Clinical implication of surgical resection for recurrent biliary tract cancer: does it work or not? Ann Gastroenterol Surg. 2017;1:164–70.CrossRef
9.
Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Surgery for recurrent biliary tract cancer: a single-center experience with 74 consecutive resections. Ann Surg. 2015;262:121–9.CrossRef
10.
Noji T, Tsuchikawa T, Mizota T, Okamura K, Nakamura T, Tamoto E, et al. Surgery for recurrent biliary carcinoma: results for 27 recurrent cases. World J Surg Oncol. 2015;13:82.CrossRef
11.
Miyazaki Y, Kokudo T, Amikura K, Kageyama Y, Takahashi A, Ohkohchi N, et al. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature. Jpn J Clin Oncol. 2017;47:206–12.CrossRef
12.
Kitano Y, Yamashita YI, Nakagawa S, Okabe H, Imai K, Chikamoto A, et al. Effectiveness of surgery for recurrent cholangiocarcinoma: a single center experience and brief literature review. Am J Surg. 2020;219:175–80.CrossRef
13.
Yamada M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival. World J Surg. 2017;41:1550–7.CrossRef
14.
Petrova E, Rückert F, Zach S, Shen YF, Weitz J, Grützmann R, et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bike duct carcinoma: a retrospective multicenter study. Langenbecks Arch Surg. 2017;42:831–40.CrossRef
15.
Yokoyama Y, Ebata T, Igami T, Sugawara G, Mizuno T, Yamaguxhi J, et al. Different clinical characteristics between distal cholangiocarcinoma and pancreatic head carcinoma with biliary obstruction. Pancreas. 2017;46:1322–6.CrossRef
16.
Schreuder AM, Engelsman AF, Roessel SV, Verheij J, Besselink MG, Van Gulik TM, et al. Treatment of mid-bile duct carcinoma: local resection or pancreatoduodenectomy? Eur J Surg Oncol. 2019;45:2180–7.CrossRef
17.
Wakai T, Sakata J, Katada T, Hirose Y, Soma D, Prasoon P, et al. Surgical management of carcinoma in situ at ductal resection margins in patients with extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2018;2:359–66.CrossRef
18.
Yasukawa K, Shimizu A, Motoyama H, Kubota K, Notake T, Fukushima K, et al. Impact of remnant carcinoma in situ at the ductal stump on long-term outcomes in patients with distal cholangiocarcinoma. World J Surg. 2021;45:291–301.CrossRef
19.
Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268–89.CrossRef
20.
Zhsng XF, Xue F, Dong DH, Weiss M, Popescu I, Marques HP, et al. Number and station of lymph node status after curative-intent resection of intrahepatic cholangiocarcinoma impact prognosis. Ann Surg. 2021;274:1187–95.CrossRef
21.
Si A, Li J, Xing X, Lei Z, Xia Y, Yan Z, et al. Effectiveness of repeat hepatic resection for patients with recurrent intrahepatic cholangiocarcinoma: factors associated with long-term outcomes. Surgery. 2017;161:897–908.CrossRef
22.
Tokuda K, Morine Y, Saito Y, Yamada S, Miyazaki K, Yamashita S, et al. Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma. Int J Clin Oncol. 2020;25:2083–9.CrossRef
23.
Zhou W, Qian L, Rong Y, Zhou Q, Shan J, Li P, et al. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiother Oncol. 2020;147:111–7.CrossRef
24.
Nakanishi Y, Okamura K, Tsuchikawa T, Nakamura T, Noji T, Asano T, et al. Time to recurrence after surgical resection and survival after recurrence among patients with perihilar and distal cholangiocarcinomas. Ann Surg Oncol. 2020;27:4171–80.CrossRef
25.
Sahara K, Tsilimigras DI, Toyoda J, Miyake K, Ethun CG, Maithel SK, et al. Defining the risk of early recurrence following curative-intent resection for distal cholangiocarcinoma. Ann Surg Oncol. 2021;28:4205–13.CrossRef
26.
Di Martino M, Koh YX, Syn N, Min Chin K, Burdió F, Sánchez Velázquez P, et al. It is lymph node ratio that determines survival and recurrence patterns in resected distal cholangiocarcinoma. A multicenter international study. Eur J Surg Oncol. 2022;48:1576–84.CrossRef
27.
Sakata J, Nomura T, Aono T, Kitami C, Yokoyama N, Minagawa M, et al. Oncological outcomes of surgery for recurrent biliary tract cancer: who are the best candidates? HPB (Oxford). 2021;23:1371–82.CrossRef
28.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–81.CrossRef
29.
Morizane C, Okusaka T, Mizusawa J, Takashima A, Ueno M, Ikeda M, et al. Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 2013;104:1211–6.CrossRef
30.
Valle JW. Advances in the treatment of metastatic or unresectable biliary tract cancer. Ann Oncol. 2010;21(Suppl 7):vii345–8.CrossRef
31.
Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;12:1707–12.CrossRef
32.
Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, et al. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24:3061–5.CrossRef
33.
Bisello S, Buwenge M, Palloni A, Autorino R, Cellini F, Macchia G, et al. Radiotherapy or chemoradiation in unresectable biliary tract cancer: a retrospective study. Anticancer Res. 2019;39:3095–100.CrossRef
34.
Wellner UF, Shen YF, Keck T, Jin WY, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today. 2017;47:271–9.CrossRef
35.
Kiriyama M, Ebata T, Aoba T, Kaneoka Y, Arai T, Shimizu Y, et al. Prognostic impact of lymph node metastasis in distal cholangiocarcinoma. Br J Surg. 2015;102:399–406.CrossRef
36.
Byrling J, Andersson R, Sasor A, Lindell G, Ansari D, Nilsson J, et al. Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma. Ann Gastroenterol. 2017;30:571–7.
37.
Bolm L, Petrova E, Weitz J, Rückert F, Wittel UA, Makowiec F, et al. Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19–9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma. HPB (Oxford). 2019;21:1513–9.CrossRef
38.
Xu S, Zhang XP, Zhao GD, Zhao ZM, Gao YX, Hu MG, et al. Development and validation of an online calculator to predict early recurrence and long-term survival in patients with distal cholangiocarcinoma after pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci. 2021. https://​doi.​org/​10.​1002/​jhbp.​1058.CrossRef
Metadata
Title
Indications for resection of recurrent lesions in patients with distal cholangiocarcinoma based on prognostic factors: a single-institute retrospective study and brief literature review
Authors
Taro Mashiko
Toshihito Ogasawara
Yoshihito Masuoka
Shigenori Ei
Shinichiro Takahashi
Masaki Mori
Kazuo Koyanagi
Seiichiro Yamamoto
Toshio Nakagohri
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2022
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/s12893-022-01879-3

Other articles of this Issue 1/2022

BMC Surgery 1/2022 Go to the issue

Research

Comparison of advanced techniques for local excision of rectal lesions: a case series

Research

The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients

Case report

Endoscopy-aided retrieval of broken drainage tube after lumbar spine surgery

Research

Outcome of Santulli enterostomy in patients with immaturity of ganglia: single institutional experience from a case series

Research

Report of 13-year survival of patients with colon and rectal cancers; lessons from Shiraz colorectal cancer surgery registry system of a level three medical center

Research

Comparison of percutaneous endoscopic thoracic decompression and posterior thoracic laminectomy for treating thoracic ossification of the ligamentum flavum: a retrospective study